ISSN: 1933-7213

Journal Home

Journal Guideline

Neurotherapeutics Q1 Unclaimed

Elsevier B.V. Netherlands

Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Neurotherapeutics is a journal indexed in SJR in Pharmacology and Neurology (clinical) with an H index of 136. It has a price of 3690 €. It has an SJR impact factor of 1,625 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 1,625.

Neurotherapeutics focuses its scope in these topics and keywords: autism, model, microglial, micefluidbased, macrophages, loss, longitudinal, lateral, kindled, monocytederived, ...

Type: Journal

Type of Copyright:

Languages: English

Open Access Policy: Open Choice

Type of publications:

Publication frecuency: -

Categories: Neurology (clinical) (Q1) Pharmacology (Q1) Pharmacology (medical) (Q1) Pharmacology (medical) (Q1)

Price

3690 €

Inmediate OA

NPD

Embargoed OA

0 €

Non OA

Metrics

1,625

SJR Impact factor

136

H Index

136

Total Docs (Last Year)

489

Total Docs (3 years)

11473

Total Refs

2758

Total Cites (3 years)

461

Citable Docs (3 years)

5.13

Cites/Doc (2 years)

84.36

Ref/Doc

Comments

No comments ... Be the first to comment!

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID *

* The email or ORCID field is only to validate the authenticity of the comment, the identity will not be public. .

Other journals with similar parameters

Pharmacological Reviews Q1
Drug Resistance Updates Q1
Annual Review of Pharmacology and Toxicology Q1
Molecular Therapy Q1
Journal for ImmunoTherapy of Cancer Q1

Compare this journals

Aims and Scope

Best articles by citations

Stuck in the Mire

The treatment of movement disorders by deep brain stimulation

Interleukin-1beta Causes Fluoxetine Resistance in an Animal Model of Epilepsy-Associated Depression

Modulation of Aversive Memory by Adult Hippocampal Neurogenesis

Approaching a new age in Duchenne muscular dystrophy treatment

MRI in multiple sclerosis: What's inside the toolbox?

Commentary: A skeptical view of experimental gene therapy to block epileptogenesis

Transplantation of GABA-producing cells for seizure control in models of temporal lobe epilepsy

Progress in Cell Grafting Therapy for Temporal Lobe Epilepsy

Beneficial Effect of Erythropoietin Short Peptide on Acute Traumatic Brain Injury

Assessment of Motor Units in Neuromuscular Disease

Neuropeptide Y overexpression using recombinant adenoassociated viral vectors

SHOW MORE ARTICLES

Deep brain stimulation for psychiatric disorders

Repetitive Transcranial Magnetic Stimulation Alleviates Neurological Deficits After Cerebral Ischemia Through Interaction Between RACK1 and BDNF exon IV by the Phosphorylation-Dependent Factor MeCP2

The hereditary inclusion body myopathy enigma and its future therapy

Immunosuppressive agents in multiple sclerosis

A Systems Approach to Drug Discovery in Alzheimer's Disease

Comparative Analysis of the Treatment of Chronic Antipsychotic Drugs on Epileptic Susceptibility in Genetically Epilepsy-prone Rats

Calpain as a therapeutic target in traumatic brain injury

Leveraging Optogenetic-Based Neurovascular Circuit Characterization for Repair

New treatments for neuromuscular disease: Optimism and obstacles

Neuroimmunotherapeutics comes of age

Erratum to: Remarkable Phenytoin Sensitivity in 4 Children with SCN8A-related Epilepsy: A Molecular Neuropharmacological Approach

The ketogenic diet: Proposed mechanisms of action